- New research accepted for presentation at AMIA 2026 demonstrates the performance of HEALWELL’s DARWEN™ AI-powered SMARTSuite, including clinical summarization results that outperformed published benchmarks for OpenAI’s GPT, DeepSeek and Llama across all three measures used to evaluate clinical summarization accuracy.
- Separate DARWEN™ AI validation research accepted for oral presentation at AI-MEDX 2026 demonstrated nearly 50% higher treatment-plan accuracy than a leading off-the-shelf general-purpose AI model in blinded clinician review, producing more clinically specific outputs, including drugs and doses.
- New DARWEN™ AI research in the Canadian Journal of Cardiology demonstrates the impact of SMART Patient ID, identifying more than 4,100 heart failure patients not receiving guideline-directed medical therapy, helping drive a 70% improvement in treatment optimization within six months.
- HEALWELL and its pharmaceutical company partners have secured multiple fall 2026 research acceptances at leading scientific forums, including EADV 2026, ACG 2026, The Menopause Society 2026 and ISPOR Europe 2026, spanning women’s health, dermatology, gastroenterology and oncology.
TORONTO, ON – September 15, 2026 – HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), a healthcare artificial intelligence company focused on preventative care, is pleased to announce new research supporting the clinical performance and real-world impact of its DARWEN™ AI platform, with studies accepted for presentation or publication across 12 medical, health informatics, artificial intelligence and health economics forums during the fall of 2026. The research demonstrates DARWEN™’s ability to translate healthcare-specific AI into clinically relevant outcomes, including performance advantages over leading general-purpose AI models in clinical summarization and treatment-plan generation, as well as measurable improvements in the identification and treatment optimization of patients with unmet clinical needs.
DARWEN™ AI is HEALWELL’s proprietary, patented and clinically validated AI platform that transforms complex structured and unstructured healthcare data into traceable, actionable knowledge. DARWEN™ powers SMART Search, SMART Summary and SMART Patient ID, helping clinicians find critical information, understand complex patient histories and identify patients with unmet clinical needs earlier.
New research being presented at AMIA 2026 demonstrates the performance of HEALWELL’s DARWEN™ AI-powered SMARTSuite, including clinical summarization results that outperformed published benchmarks for OpenAI’s GPT, DeepSeek and Llama across all three measures used to evaluate clinical summarization accuracy. The three measures, ROUGE-1, ROUGE-2 and ROUGE-L, are used to evaluate the quality and accuracy of generated clinical summaries. DARWEN™ demonstrated an average 43% improvement in ROUGE-1, an average 21% improvement in ROUGE-2 and an average 43% improvement in ROUGE-L compared with the published benchmarks among the models evaluated.(1)
Separate research accepted for oral presentation at AI-MEDX 2026 demonstrated nearly 50% higher treatment-plan accuracy than a leading off-the-shelf general-purpose AI model in blinded clinician review, producing more clinically specific outputs, including drugs and doses(2).
New research published in the Canadian Journal of Cardiology demonstrates the real-world impact of HEALWELL’s DARWEN™ AI-powered SMART Patient ID in identifying patients with unmet clinical needs. The study identified more than 4,100 patients with heart failure who were not receiving guideline-directed medical therapy, enabling targeted clinical intervention and helping drive a 70% improvement in treatment optimization within six months. The findings demonstrate the potential of AI-powered patient identification to move beyond information retrieval and support proactive, evidence-based care for patients who may otherwise remain undertreated.(3)
Aaron Leibtag, Head of Global Health Systems AI Strategy at HEALWELL and Co-Founder of Pentavere, said, “DARWEN™’s continued clinical and scientific validation comes as the platform gains commercial traction across health systems and life sciences. Outperforming published benchmarks for leading foundation models while demonstrating real-world patient impact validates our strategy. HEALWELL recently announced a multi-year deployment of DARWEN™-powered SMART Search and SMART Summary across Iowa’s statewide Health Information Exchange, which receives data from 115 hospitals, as well as DARWEN™-powered clinical trial matching through WELLTRUST™’s network of more than 100,000 consented patients. Together, these deployments demonstrate HEALWELL’s strategy of translating DARWEN™’s scientific differentiation into commercial scale.”
Dr. Christopher Pettengell, Chief Medical Officer of HEALWELL, commented, “The important question for clinical AI is not whether a model can produce an answer that sounds medically plausible. It is whether it can consistently identify the right information, preserve the clinical context and provide the specificity required for clinicians to act. Outperforming published benchmarks for leading foundation models while demonstrating real-world patient impact validates our strategy, build the evidence first, then scale what works across health systems and life sciences.”
Dr. Pettengell added, “Our upcoming peer-reviewed presentations and publications provide further evidence that purpose-built, clinically validated AI can meaningfully outperform general-purpose approaches on these dimensions. Combined with the breadth of therapeutic-area research being presented this fall, we believe this reinforces DARWEN™ as an increasingly differentiated clinical intelligence AI platform.”
Fall 2026 Program: Broad Scientific Validation Across Healthcare and Life Sciences
HEALWELL’s fall 2026 clinical and AI scientific program includes research accepted at 12 global programs, including AMIA 2026, AI-MEDX 2026, EADV 2026, ACG 2026, The Menopause Society 2026, ISPOR Europe 2026 and the Canadian Cardiovascular Congress.
These DARWEN™ AI-powered real-world evidence & AI demonstration studies span women’s health, dermatology, inflammatory bowel disease, oncology, heart failure and rare disease, demonstrating the platform’s breadth across patient identification, clinical decision support, research and evidence generation. The studies include collaborations with leading global pharmaceutical companies including AstraZeneca, Bayer, Galderma, UCB, Takeda, Arcutis and Merck.
Together, the fall scientific program and recent commercial deployments demonstrate HEALWELL’s progression from scientific validation to enterprise deployment and commercial scale, while expanding DARWEN™ across health systems and life sciences. HEALWELL expects to provide additional details on individual studies and results as they are presented and published.
Footnotes:
(1) DARWEN™ achieved a ROUGE-1 score of 59.8, compared with published benchmarks of 41.8 for OpenAI’s GPT, 43.5 for Llama and 39.9 for DeepSeek; DARWEN™ achieved a ROUGE-2 score of 37.0, compared with 34.3 for GPT, 28.5 for Llama and 29.8 for DeepSeek; and DARWEN™ achieved a ROUGE-L score of 48.8, compared with 36.8 for GPT, 29.8 for Llama and 36.6 for DeepSeek.
(2) DARWEN™ achieved an accuracy score of 54.7% versus Meta-Llama-3-70B-Instruct score of 37.3%
(3) O. Sergerie, S. Goodman, S. Zieroth, R. Choi, A. Gupta, Y. Khaykin, A.K. Hhameed, K. Leblanc, M. McDonald, C. Pettengell, R. Roy, M. Tan, A.M. Yip, J.E. Ezekowitz, A. Ducharme, A Natural Language Processing–Driven Electronic Medical Record Program to Optimize Medical Therapy for Heart Failure in Community Practices, CJC Open (2026), doi: https://doi.org/10.1016/j.cjco.2026.07.003.
About HEALWELL AI
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company’s road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit https://healwell.ai/.
Forward Looking Statements
Certain statements in this press release constitute “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws, and are subject to risks and uncertainties that may cause actual results to differ materially from those contemplated by such statements. Forward-looking statements in this press release include but is not limited to, statements related to: the ambition to reach approximately one million consented patients ; the anticipated development, timing, commercialization and adoption of the “Patient Recruitment Solved” offering and other CRO-facing services; plans for U.S. and international expansion, including European regulatory readiness; the anticipated benefits, functionality and adoption of the WELLTRUST™ platform generally; the expected expansion of consent capture into diagnostics, telehealth, and patient app experiences; the anticipated capabilities of the DARWEN™ platform to match trial protocols against a consented patient population; and the positioning of WELLTRUST™ as one of the largest consented, research-ready patient networks in North America are based on assumptions, expectations, estimates and projections as of the date of this press release and should not be read as guarantees of future results or performance. Forward-looking statements are often, but not always, identified by words or phrases such as “targeting”, “ambition”, “roadmap”, “accelerate”, “expand”, “enable”, “designed to”, “positioning”, “plan”, “potential” or variations of such words and phrases or statements that certain future conditions, actions, events or results “will”, “may”, “could”, “would”, “should”, “might” or “can” be taken, occur or be achieved, or the negative of any of these terms. The absence of such words does not mean a statement is not forward-looking. Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by WELL and HEALWELL as of the date of such statements, are outside of WELL’s and HEALWELL’s control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: (i) HEALWELL’s ability to maintain and leverage its relationships with its commercial partners, including WELL; (ii) the continued adoption of the software, tools and solutions created by WELL, HEALWELL and their subsidiaries, including by patients, clinics, CROs, and trial sponsors; (iii) the stability of general economic and market conditions; (iv) sufficiency of working capital and access to financing to support WELL and HEALWELL’s existing operations and strategic plan; (v) WELL and HEALWELL’s ability to comply with applicable laws and regulations, including those relating to privacy and patient data, in Canada and in any jurisdictions targeted for international expansion; (vi) HEALWELL’s continued compliance with third party intellectual property rights; (vii) the effects of competition in the industry; (viii) the requirement for increasingly innovative product solutions and service offerings and HEALWELL’s ability to continue to develop and commercialize them; (ix) technologies, including EMR connectivity and data refresh capabilities, working as intended or at all; (x) trends in customer growth and the adoption of new technologies in the industry; and (xi) that the risk factors noted below, collectively, do not have a material impact on WELL’s or HEALWELL’s business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the control of WELL and HEALWELL, could cause the actual results of WELL and HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to: (i) changes in customer demand or purchasing cycles within the healthcare software and clinical research markets; (ii) WELL and HEALWELL’s ability to attract, retain and expand relationships with key customers, including CROs, SMOs and trial sponsors; (iii) the timing, success and adoption of product deployments and software integrations, including EMR connectivity across WELL’s clinic network; (iv) competition and pricing pressures; (v) risks associated with international expansion, including regulatory and market-entry risk; (vi) the ability to recruit and retain key personnel; (vii) the risk that patients who have consented may withdraw their consent, or that consent rates may decline as the platform scales beyond early adopters; and (viii) other factors which are discussed under the section entitled “Risk Factors” in HEALWELL’s and WELL’s most recent annual information forms, dated March 18, 2026 for HEALWELL and dated March 19, 2026 for WELL, which are available under HEALWELL’s and WELL’s respective SEDAR+ profiles at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect WELL or HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. WELL and HEALWELL disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai